Premium
Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime
Author(s) -
Quach Henry T.,
Esbenshade Adam J.,
Zhao Zhiguo,
Banerjee Ritu
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27750
Subject(s) - cefepime , medicine , piperacillin/tazobactam , vancomycin , piperacillin , tazobactam , acute kidney injury , incidence (geometry) , antibiotics , staphylococcus aureus , microbiology and biotechnology , genetics , physics , optics , antibiotic resistance , imipenem , bacteria , pseudomonas aeruginosa , biology
There is mounting evidence that combination of antibiotic therapy with vancomycin and piperacillin/tazobactam (pip/tazo) is associated with acute kidney injury (AKI). To determine whether vancomycin plus pip/tazo is associated with higher rates of AKI compared to vancomycin plus cefepime among pediatric hematology/oncology (heme/onc) patients, we examined 121 heme/onc patients receiving at least two consecutive days of therapy with vancomycin and either pip/tazo or cefepime. Rate of AKI was higher in the pip/tazo than the cefepime group (4/27 [14.8%] vs 2/94 [2.1%], P = 0.022).